11 research outputs found

    Systems analysis and improvement to optimize pMTCT (SAIA): a cluster randomized trial

    Get PDF
    BACKGROUND: Despite significant increases in global health investment and the availability of low-cost, efficacious interventions to prevent mother-to-child HIV transmission (pMTCT) in low- and middle-income countries with high HIV burden, the translation of scientific advances into effective delivery strategies has been slow, uneven and incomplete. As a result, pediatric HIV infection remains largely uncontrolled. A five-step, facility-level systems analysis and improvement intervention (SAIA) was designed to maximize effectiveness of pMTCT service provision by improving understanding of inefficiencies (step one: cascade analysis), guiding identification and prioritization of low-cost workflow modifications (step two: value stream mapping), and iteratively testing and redesigning these modifications (steps three through five). This protocol describes the SAIA intervention and methods to evaluate the intervention’s impact on reducing drop-offs along the pMTCT cascade. METHODS: This study employs a two-arm, longitudinal cluster randomized trial design. The unit of randomization is the health facility. A total of 90 facilities were identified in Côte d’Ivoire, Kenya and Mozambique (30 per country). A subset was randomly selected and assigned to intervention and comparison arms, stratified by country and service volume, resulting in 18 intervention and 18 comparison facilities across all three countries, with six intervention and six comparison facilities per country. The SAIA intervention will be implemented for six months in the 18 intervention facilities. Primary trial outcomes are designed to assess improvements in the pMTCT service cascade, and include the percentage of pregnant women being tested for HIV at the first antenatal care visit, the percentage of HIV-infected pregnant women receiving adequate prophylaxis or combination antiretroviral therapy in pregnancy, and the percentage of newborns exposed to HIV in pregnancy receiving an HIV diagnosis eight weeks postpartum. The Consolidated Framework for Implementation Research (CFIR) will guide collection and analysis of qualitative data on implementation process. DISCUSSION: This study is a pragmatic trial that has the potential benefit of improving maternal and infant outcomes by reducing drop-offs along the pMTCT cascade. The SAIA intervention is designed to provide simple tools to guide decision-making for pMTCT program staff at the facility level, and to identify low cost, contextually appropriate pMTCT improvement strategies. TRIAL REGISTRATION: ClinicalTrials.gov NCT0202365

    Efficacy of Cervical Cancer Screening to Prevent Cervical Cancer Mortality Among Women Ages 55 to 79 Years: A Population-Based, Case-Control Study

    Full text link
    Thesis (Ph.D.)--University of Washington, 2013Aim. Though cervical cytology screening has been shown to reduce cervical cancer incidence and mortality among reproductive-age women, there are but limited data regarding the efficacy of screening older women. Analyses from Sweden and Finland suggest that participation by older women in organized cytology screening programs reduces the incidence of cervical cancer by 51-64%. In the United States, results from Kamineni and colleagues suggest that cytology screening reduces cervical cancer incidence by 77% among women ages 55-79 years. We sought to quantify the efficacy of cervical cancer screening among older American women with respect to mortality. Methods. Among enrollees of two U.S. health plans, we compared cervical screening histories of women ages 55-79 who died of cervical cancer during 1980-2010 (cases) to those of women who were at risk of developing this malignancy (controls). Controls were sampled from women with an intact cervix, matched 2:1 to cases on health plan, age, and enrollment duration. Medical records were reviewed to ascertain each woman's receipt of cytology screening during the detectable pre-clinical phase (DPP), estimated to be the 5 to 7 years prior to diagnosis during which cervical neoplasia is asymptomatic but cytologically detectable. Logistic regression models were used to estimate the risk of cervical cancer mortality associated with screening. Results. 39 cases and 80 controls were eligible for the study. Screening during the presumed DPP was associated with a 74% (95% CI: 37-90%) reduction in cervical cancer mortality, adjusting for matching characteristics and covariates that were associated with case status (smoking, marital status, race/ethnicity). Significance. Screening of older women by means of cervical cytology was strongly associated with reduced cervical cancer mortality. These results provide a minimum efficacy estimate of human papillomavirus DNA screening - a more sensitive test that may be increasingly utilized in the future -- to reduce mortality among older women

    Health facility factors and quality of PMTCT services.dta

    Full text link
    These data were collected from n=60 health facilities in Kenya, Mozambique, and CĂ´te d'Ivoire (20 per country) during in-person visits between May 2013 and January 2014. Whenever possible, data were obtained directly from the facility registry. Facility staff (facility director, director of Maternal & Child Health (MCH) services, and/or director of PMTCT services, as appropriate) were interviewed to obtain any data that was not or could not be documented in the registry

    A cross-sectional analysis of Trichomonas vaginalis infection among heterosexual HIV-1 serodiscordant African couples.

    Full text link
    OBJECTIVES: Trichomonas vaginalis is the most prevalent curable STI worldwide and has been associated with adverse health outcomes and increased HIV-1 transmission risk. We conducted a cross-sectional analysis among couples to assess how characteristics of both individuals in sexual partnerships are associated with the prevalence of male and female T. vaginalis infection. METHODS: African HIV-1 serodiscordant heterosexual couples were concurrently tested for trichomoniasis at enrolment into two clinical trials. T. vaginalis testing was by nucleic acid amplification or culture methods. Using Poisson regression with robust standard errors, we identified characteristics associated with trichomoniasis. RESULTS: Among 7531 couples tested for trichomoniasis, 981 (13%) couples contained at least one infected partner. The prevalence was 11% (n=857) among women and 4% (n=319) among men, and most infected individuals did not experience signs or symptoms of T. vaginalis. Exploring concordance of T. vaginalis status within sexual partnerships, we observed that 61% (195/319) of T. vaginalis-positive men and 23% (195/857) of T. vaginalis-positive women had a concurrently infected partner. In multivariable analysis, having a T. vaginalis-positive partner was the strongest predictor of infection for women (relative risk (RR) 4.70, 95% CI 4.10 to 5.38) and men (RR 10.09, 95% CI 7.92 to 12.85). For women, having outside sex partners, gonorrhoea, and intermediate or high Nugent scores for bacterial vaginosis were associated with increased risk of trichomoniasis, whereas age 45 years and above, being married, having children and injectable contraceptive use were associated with reduced trichomoniasis risk. Additionally, women whose male partners were circumcised, had more education or earned income had lower risk of trichomoniasis. CONCLUSIONS: We found that within African HIV-1 serodiscordant heterosexual couples, the prevalence of trichomoniasis was high among partners of T. vaginalis-infected individuals, suggesting that partner services could play an important role identifying additional cases and preventing reinfection. Our results also suggest that male circumcision may reduce the risk of male-to-female T. vaginalis transmission
    corecore